RVX has a solid asset: and an FDA stamp of approval for its molecule.  It is not going bankrupt.  It's main share holder Hepalink will make sure of that.

The shocker is that it is the only company I know of, with a breakthrough designation molecule, that has a US$100 million market cap.  

But the company needs to raise capital.  The only way they put a floor on this, is if they can get fresh money at the last financing (done at 85 cents).  If Hepalink writes them a check, then the shares will bounce back hard.  It would not surprise me if there will be a big discussion over the weekend about this between Calgary and Shenzhen!